A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia

Mazie Tsang, Sameer A Parikh

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune complications such as autoimmune hemolytic anemia, immune thrombocytopenia, pure red cell aplasia, and autoimmune granulocytopenia. It is critical to diagnose cytopenias from these secondary complications of CLL accurately, since prognosis and therapy are substantially different from patients who have cytopenias due to extensive bone marrow infiltration by CLL. The pathogenesis of autoimmune cytopenias in CLL is complex; and it involves antigen presentation by CLL cells to polyclonal B cells resulting in production of autoantibody, and alteration of the T cell milieu tilting the balance in favor of an autoimmune response. Traditional therapy of autoimmune complications in CLL consists of immunosuppression with corticosteroids and/or anti-CD20 monoclonal antibodies. In patients who have a suboptimal response, treating the underlying CLL is generally effective in ameliorating secondary cytopenias. Although novel oral therapies such as ibrutinib, idelalisib, and venetoclax have been shown to be extremely effective in the management of CLL, prospective data from larger numbers of patients with longer follow-up are needed prior to recommending their routine use in the management of autoimmune cytopenias in CLL.

Original languageEnglish (US)
Pages (from-to)29-38
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Volume12
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Pure Red-Cell Aplasia
Autoimmune Hemolytic Anemia
Agranulocytosis
Idiopathic Thrombocytopenic Purpura
Antigen Presentation
Autoimmunity
Autoantibodies
Immunosuppression
Adrenal Cortex Hormones
B-Lymphocytes
Therapeutics
Bone Marrow
Monoclonal Antibodies
T-Lymphocytes

Keywords

  • Autoimmune cytopenias
  • Autoimmune hemolytic anemia
  • Immune thrombocytopenia
  • Pure red cell aplasia
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. / Tsang, Mazie; Parikh, Sameer A.

In: Current Hematologic Malignancy Reports, Vol. 12, No. 1, 01.02.2017, p. 29-38.

Research output: Contribution to journalReview article

@article{2d9382c295af48dbb6060e5b99a0b0e1,
title = "A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia",
abstract = "Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune complications such as autoimmune hemolytic anemia, immune thrombocytopenia, pure red cell aplasia, and autoimmune granulocytopenia. It is critical to diagnose cytopenias from these secondary complications of CLL accurately, since prognosis and therapy are substantially different from patients who have cytopenias due to extensive bone marrow infiltration by CLL. The pathogenesis of autoimmune cytopenias in CLL is complex; and it involves antigen presentation by CLL cells to polyclonal B cells resulting in production of autoantibody, and alteration of the T cell milieu tilting the balance in favor of an autoimmune response. Traditional therapy of autoimmune complications in CLL consists of immunosuppression with corticosteroids and/or anti-CD20 monoclonal antibodies. In patients who have a suboptimal response, treating the underlying CLL is generally effective in ameliorating secondary cytopenias. Although novel oral therapies such as ibrutinib, idelalisib, and venetoclax have been shown to be extremely effective in the management of CLL, prospective data from larger numbers of patients with longer follow-up are needed prior to recommending their routine use in the management of autoimmune cytopenias in CLL.",
keywords = "Autoimmune cytopenias, Autoimmune hemolytic anemia, Immune thrombocytopenia, Pure red cell aplasia, Small lymphocytic lymphoma",
author = "Mazie Tsang and Parikh, {Sameer A}",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s11899-017-0366-1",
language = "English (US)",
volume = "12",
pages = "29--38",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia

AU - Tsang, Mazie

AU - Parikh, Sameer A

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune complications such as autoimmune hemolytic anemia, immune thrombocytopenia, pure red cell aplasia, and autoimmune granulocytopenia. It is critical to diagnose cytopenias from these secondary complications of CLL accurately, since prognosis and therapy are substantially different from patients who have cytopenias due to extensive bone marrow infiltration by CLL. The pathogenesis of autoimmune cytopenias in CLL is complex; and it involves antigen presentation by CLL cells to polyclonal B cells resulting in production of autoantibody, and alteration of the T cell milieu tilting the balance in favor of an autoimmune response. Traditional therapy of autoimmune complications in CLL consists of immunosuppression with corticosteroids and/or anti-CD20 monoclonal antibodies. In patients who have a suboptimal response, treating the underlying CLL is generally effective in ameliorating secondary cytopenias. Although novel oral therapies such as ibrutinib, idelalisib, and venetoclax have been shown to be extremely effective in the management of CLL, prospective data from larger numbers of patients with longer follow-up are needed prior to recommending their routine use in the management of autoimmune cytopenias in CLL.

AB - Chronic lymphocytic leukemia (CLL) is frequently associated with autoimmune complications such as autoimmune hemolytic anemia, immune thrombocytopenia, pure red cell aplasia, and autoimmune granulocytopenia. It is critical to diagnose cytopenias from these secondary complications of CLL accurately, since prognosis and therapy are substantially different from patients who have cytopenias due to extensive bone marrow infiltration by CLL. The pathogenesis of autoimmune cytopenias in CLL is complex; and it involves antigen presentation by CLL cells to polyclonal B cells resulting in production of autoantibody, and alteration of the T cell milieu tilting the balance in favor of an autoimmune response. Traditional therapy of autoimmune complications in CLL consists of immunosuppression with corticosteroids and/or anti-CD20 monoclonal antibodies. In patients who have a suboptimal response, treating the underlying CLL is generally effective in ameliorating secondary cytopenias. Although novel oral therapies such as ibrutinib, idelalisib, and venetoclax have been shown to be extremely effective in the management of CLL, prospective data from larger numbers of patients with longer follow-up are needed prior to recommending their routine use in the management of autoimmune cytopenias in CLL.

KW - Autoimmune cytopenias

KW - Autoimmune hemolytic anemia

KW - Immune thrombocytopenia

KW - Pure red cell aplasia

KW - Small lymphocytic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85012941537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012941537&partnerID=8YFLogxK

U2 - 10.1007/s11899-017-0366-1

DO - 10.1007/s11899-017-0366-1

M3 - Review article

C2 - 28197963

AN - SCOPUS:85012941537

VL - 12

SP - 29

EP - 38

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -